189 related articles for article (PubMed ID: 21440449)
21. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
DiPippo AJ; Patel NK; Barnett CM
Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
24. Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
Węsierska-Gądek J; Mauritz M
Future Med Chem; 2016 Jan; 8(1):55-72. PubMed ID: 26692095
[TBL] [Abstract][Full Text] [Related]
25. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
27. Cell Cycle Regulation in Treatment of Breast Cancer.
Cai Z; Liu Q
Adv Exp Med Biol; 2017; 1026():251-270. PubMed ID: 29282688
[TBL] [Abstract][Full Text] [Related]
28. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
30. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
31. Fluorescent phosphoinositide 3-kinase inhibitors suitable for monitoring of intracellular distribution.
Kim D; Lee H; Jun H; Hong SS; Hong S
Bioorg Med Chem; 2011 Apr; 19(8):2508-16. PubMed ID: 21459582
[TBL] [Abstract][Full Text] [Related]
32. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.
Sirajuddin P; Das S; Ringer L; Rodriguez OC; Sivakumar A; Lee YC; Üren A; Fricke ST; Rood B; Ozcan A; Wang SS; Karam S; Yenugonda V; Salinas P; Petricoin E; Pishvaian M; Lisanti MP; Wang Y; Schlegel R; Moasser B; Albanese C
Cell Cycle; 2012 Oct; 11(20):3801-9. PubMed ID: 22983062
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
34. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
35. Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors.
Sharma P; Alsharif S; Bursch K; Parvathaneni S; Anastasakis DG; Chahine J; Fallatah A; Nicolas K; Sharma S; Hafner M; Kallakury B; Chung BM
Sci Rep; 2019 Oct; 9(1):14650. PubMed ID: 31601969
[TBL] [Abstract][Full Text] [Related]
36. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.
Ringer L; Sirajuddin P; Heckler M; Ghosh A; Suprynowicz F; Yenugonda VM; Brown ML; Toretsky JA; Uren A; Lee Y; MacDonald TJ; Rodriguez O; Glazer RI; Schlegel R; Albanese C
Cancer Biol Ther; 2011 Nov; 12(9):818-26. PubMed ID: 21885916
[TBL] [Abstract][Full Text] [Related]
37. CDK4/6 inhibitors in breast cancer.
Dukelow T; Kishan D; Khasraw M; Murphy CG
Anticancer Drugs; 2015 Sep; 26(8):797-806. PubMed ID: 26053278
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM; Gianella-Borradori A
Expert Opin Investig Drugs; 2005 Apr; 14(4):457-77. PubMed ID: 15882121
[TBL] [Abstract][Full Text] [Related]
39. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
[TBL] [Abstract][Full Text] [Related]
40. Rational design of a cyclin A fluorescent peptide sensor.
Pazos E; Pérez M; Gutiérrez-de-Terán H; Orzáez M; Guevara T; Mascareñas JL; Vázquez ME
Org Biomol Chem; 2011 Oct; 9(22):7629-32. PubMed ID: 21863156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]